History of myeloid-derived suppressor cells
Open accessThe DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.
Abstract
Tumour-induced granulocytic hyperplasia is associated with tumour vasculogenesis and escape from immunity via T cell suppression. Initially, these myeloid cells were identified as granulocytes or monocytes; however, recent studies have revealed that this hyperplasia is associated with populations of multipotent progenitor cells that have been identified as myeloid-derived suppressor cells (MDSCs). The study of MDSCs has provided a wealth of information regarding tumour pathobiology, has extended our understanding of neoplastic progression and has modified our approaches to immune adjuvant therapy. In this Timeline article, we discuss the history of MDSCs, their influence on tumour progression and metastasis, and the crosstalk between tumour cells, MDSCs and the host macroenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Myeloid-derived suppressor cells (MDSCs), a heterogeneous group of immune cells from the myeloid lineage, are a major component of the immunosuppressive TME [93].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [93]
The cited source says what the claim attributes to it.
In the citing paper
“The TME is immunosuppressive, thus rendering the immune system less effective in killing cancer cells.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationMolecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Goycoolea, A. (1997) · Cited by 3,615
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S.-I., Kitamura, Y., Yoshida, N., Kikutani, H., & Kishimoto, T. (1996) · Nature · doi:10.1038/382635a0 · Cited by 2,338
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Asahara, T., Takahashi, T., Masuda, H., Kalka, C., Chen, D., Iwaguro, H., Inai, Y., Silver, M., & Isner, J. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.14.3964 · Cited by 1,856
Research works printed but not linked: 1
- Sonnenfeld A Leukamische reaktiones bei carcinoma Zeitschrift f Klin Med 1929 111
Cited by
Items 301–400 of 1,000
Current understandings and clinical translation of nanomedicines for breast cancer therapy
Jiang, Y., Jiang, Z., Wang, M., & Ma, L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114034 · Cited by 72
Neutrophils at the Crossroads: Unraveling the Multifaceted Role in the Tumor Microenvironment
Awasthi, D., & Sarode, A. Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052929 · Cited by 71
Li, S., Wang, N., Tan, H., Chueng, F., Zhang, Z., Yuen, M., & Feng, Y. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.112 · Cited by 69
Audrito, V., Managò, A., Gaudino, F., Sorci, L., Messana, V. G., Raffaelli, N., & Deaglio, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01720 · Cited by 64
Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer
Bergenfelz, C., Roxå, A., Mehmeti, M., Leandersson, K., & Larsson, A.-M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02472-z · Cited by 67
Li, Y., Li, M., Su, K., Zong, S., Zhang, H., & Xiong, L. (2023) · Theranostics · doi:10.7150/thno.82700 · Cited by 69
Pan, T. S., Li, Z., Wu, S., Cao, Y., Yang, Q., Cai, Z., Cai, X., Zhao, W., Ma, N., Zhang, W., et al. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12790 · Cited by 67
Eksioglu, E. A., Chen, X., Heider, K.-H., Rueter, B., McGraw, K. L., Basiorka, A. A., Wei, M., Burnette, A., Cheng, P., Lancet, J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.21 · Cited by 66
Zhang, L., Yang, L., Wan, S., Yang, Q., Xiao, Y., Deng, H., & Sun, Z. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c02050 · Cited by 66
Hofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 69
Immunomodulatory‐Photodynamic Nanostimulators for Invoking Pyroptosis to Augment Tumor Immunotherapy
Qiu, W., Su, W., Xu, J., Liang, M., Ma, X., Xue, P., Kang, Y., Sun, Z., & Xu, Z. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202201233 · Cited by 66
Current status of immunotherapy
Suzuki, S., Ishida, T., Yoshikawa, K., & Ueda, R. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv201 · Cited by 71
Immune Modulation of Cardiac Repair and Regeneration: The Art of Mending Broken Hearts
Zlatanova, I., Pinto, C., & Silvestre, J. (2016) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2016.00040 · Cited by 70
Chang, C. F., Yang, Y., Chiu, C.-J., Lu, L., Liao, C., Liang, C., Hsu, C., & Cheng, A. (2017) · International Journal of Cancer · doi:10.1002/ijc.31216 · Cited by 67
Myeloid-derived suppressor cells in transplantation: the dawn of cell therapy
Zhang, W., Li, J., Qi, G., Tu, G.-W., Yang, C., & Xu, M. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1395-9 · Cited by 66
A clinical and biological perspective of human myeloid-derived suppressor cells in cancer
Shipp, C., Speigl, L., Janssen, N., Martens, A., & Pawelec, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2278-y · Cited by 69
Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives
Koinis, F., Xagara, A., Chantzara, E., Leontopoulou, V., Aidarinis, C., & Kotsakis, A. P. (2021) · Cells · doi:10.3390/cells11010020 · Cited by 70
Gunaydin, G., Kesikli, S. A., & Guc, D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1034918 · Cited by 59
Nagaraj, A. S., Lahtela, J., Hemmes, A., Pellinen, T., Blom, S., Devlin, J. R., Salmenkivi, K., Kallioniemi, O., Mäyränpää, M. I., Närhi, K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.059 · Cited by 64
Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer
Chaib, M., Chauhan, S. C., & Makowski, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00351 · Cited by 67
Lin, L., Chen, S., Wang, H., Gao, B., Kallakury, B., Bhuvaneshwar, K., Cahn, K., Gusev, Y., Wang, X., Wu, Y., et al. (2021) · Theranostics · doi:10.7150/thno.49819 · Cited by 64
“These myeloid progenitors can be identified in mice by the expression of Gr-1 and CD11b on recognized granulocytic and monocytic subsets [39, 40].”
BackgroundThe complex roles of efferocytosis in cancer development, metastasis, and treatment
Tajbakhsh, A., Gheibi hayat, S. M., Movahedpour, A., Savardashtaki, A., Loveless, R., Barreto, G. E., Teng, Y., & Sahebkar, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111776 · Cited by 64
Huang, W., Sundquist, J., Sundquist, K., & Ji, J. (2020) · Nature Communications · doi:10.1038/s41467-020-17028-4 · Cited by 65
Grauslund, J. H., Holmström, M. O., Jørgensen, N. G. D., Klausen, U., Weis-Banke, S. E., Fassi, D. E., Schöllkopf, C., Clausen, M. B., Gjerdrum, L. M. R., Breinholt, M. F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637420 · Cited by 67
3D Tumor Spheroid and Organoid to Model Tumor Microenvironment for Cancer Immunotherapy
Zhu, Y., Kang, E., Wilson, M., Basso, T., Chen, E., Yu, Y., & Li, Y.-R. (2022) · Organoids · doi:10.3390/organoids1020012 · Cited by 66
Multiple cancer cell types release LIF and Gal3 to hijack neural signals
Xu, Q., Cao, Y., Kong, F., Liu, J., Chen, X., Zhao, Y., Lai, C., Zhou, X., Hu, H., Fu, W., et al. (2024) · Cell Research · doi:10.1038/s41422-024-00946-z · Cited by 65
Melanoma induced immunosuppression is mediated by hematopoietic dysregulation
Kamran, N., Li, Y., Sierra, M., Alghamri, M. S., Kadiyala, P., Appelman, H. D., Edwards, M. B., Lowenstein, P. R., & Castro, M. G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1408750 · Cited by 67
Li, C., You, X., Xu, X., Wu, B., Liu, Y., Tong, T., Chen, J., Li, Y., Dai, C., Ye, Z., et al. (2022) · Advanced Science · doi:10.1002/advs.202104134 · Cited by 64
Tang, Y., Cui, G., Liu, H., Han, Y., Cai, C., Feng, Z., Shen, H., & Zeng, S. (2024) · 癌症:英文版 · doi:10.1002/cac2.12546 · Cited by 65
Yu, H., Liu, Y., McFarland, B. C., Deshane, J. S., Hurst, D. R., Ponnazhagan, S., Benveniste, E. N., & Qin, H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0004 · Cited by 65
Shrestha, S., Noh, J. M., Kim, S., Ham, H.-Y., Kim, Y.-J., Yun, Y.-J., Kim, M.-J., Kwon, M., Song, D., & Hong, C.-W. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1067744 · Cited by 62
Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy
Baniyash, M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1849-y · Cited by 62
Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/PI3K/AKT/STAT3 Signaling
Zhai, N., Li, H., Song, H., Yang, Y., Cui, A., Li, T., Niu, J., Crispe, I. N., Su, L., & Tu, Z. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170516 · Cited by 63
Myeloid‐Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets
Bizymi, N., Bjelica, S., Kittang, A. O., Mojsilović, S. B., Velegraki, M., Pontikoglou, C. G., Roussel, M., Ersvær, E., Santibanez, J. F., Lipoldová, M., et al. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000168 · Cited by 61
Huaux, F., de Bousies, V. D., Parent, M.-A., Orsi, M., Uwambayinema, F., Devosse, R., Ibouraadaten, S., Yakoub, Y., Panin, N., Palmai‐Pallag, M., et al. (2015) · Particle and Fibre Toxicology · doi:10.1186/s12989-016-0158-0 · Cited by 65
Gao, W.-F., Zhang, X., Yang, W., Dou, D., Zhang, H., Tang, Y., Zhong, W., Meng, J., Bai, Y., Liu, Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0676-z · Cited by 62
Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers
He, L., Zhong, Z., Chen, M., Liang, Q., Wang, Y., & Tan, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.775084 · Cited by 64
Immunocytes in the tumor microenvironment: recent updates and interconnections
Yu, J., Fu, L., Wu, R., Che, L., Liu, G., Ran, Q., Xia, Z., Liang, X., & Zhao, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1517959 · Cited by 74
Personalized approaches to active immunotherapy in cancer
Ophir, E., Bobisse, S., Coukos, G., Harari, A., & Kandalaft, L. E. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.07.004 · Cited by 66
Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy
Jiang, J., Huang, Y., Zeng, Z., & Zhao, C. (2023) · ACS Nano · doi:10.1021/acsnano.2c07607 · Cited by 59
Zhang, Y., & Xu, J. (2018) · Royal Society Open Science · doi:10.1098/rsos.170986 · Cited by 58
MiRNAs at the Crossroads between Innate Immunity and Cancer: Focus on Macrophages
Curtale, G. (2018) · Cells · doi:10.3390/cells7020012 · Cited by 62
Heim, C. E., West, S. C., Ali, H., & Kielian, T. (2018) · Infection and Immunity · doi:10.1128/iai.00684-18 · Cited by 62
Li, X., Xing, Y.-F., Lei, A.-H., Xiao, Q., Lin, Z.-H., Hong, Y.-F., Wu, X.-Y., & Zhou, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15456 · Cited by 56
Surface Oncology, 5. H. S., Rausch, M. P., & Hastings, K. T. (2017) · Codon Publications eBooks · doi:10.15586/codon.cutaneousmelanoma.2017.ch9 · Cited by 73
Hsieh, C., Hung, C., Chiang, M., Tsai, Y.-C., & He, J.-T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205079 · Cited by 60
Ravindranathan, S., Nguyen, K. G., Kurtz, S. L., Frazier, H. N., Smith, S. G., Koppolu, B., Rajaram, N., & Zaharoff, D. A. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1054-3 · Cited by 56
Myeloid-Derived Suppressor Cells: A Multifaceted Accomplice in Tumor Progression
Cheng, J., Yuan, Y., Zhu, B., & Jia, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.740827 · Cited by 58
Liu, Y., Wei, J., Guo, G., & Zhou, J. (2015) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2015.1059442 · Cited by 60
The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients
Tobin, R. P., Davis, D. M., Jordan, K. R., & McCarter, M. D. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5vmr1016-449r · Cited by 57
Defective TGF-β Signaling in Bone Marrow–Derived Cells Prevents Hedgehog-Induced Skin Tumors
Fan, Q., Gu, D., Liu, H., Yang, L., Zhang, X., Yöder, M. C., Kaplan, M. H., & Xie, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2134-t · Cited by 58
Colligan, S. H., Amitrano, A. M., Zollo, R. A., Peresie, J., Kramer, E. D., Morreale, B. G., Barbi, J. J., Singh, P. K., Yu, H., Wang, J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158661 · Cited by 56
A New VISTA on combination therapy for negative checkpoint regulator blockade
Deng, J., Mercier, I. L., Kuta, A., & Noelle, R. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0190-5 · Cited by 57
Yang, Q., Li, X., Chen, H., Cao, Y., Xiao, Q., He, Y., Wei, J., & Zhou, J. (2017) · Oncogene · doi:10.1038/onc.2016.448 · Cited by 59
LILRB4 promotes tumor metastasis by regulating MDSCs and inhibiting miR-1 family miRNAs
Su, M., Kumata, S., Endo, S., Okada, Y., & Takai, T. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2060907 · Cited by 56
Edgington‐Mitchell, L. E., Rautela, J., Duivenvoorden, H. M., Jayatilleke, K. M., van der Linden, W. A., Verdoes, M., Bogyo, M. S., & Parker, B. S. (2015) · Oncotarget · doi:10.18632/oncotarget.4714 · Cited by 57
Menezes, M. E., Das, S. K., Minn, I., Emdad, L., Wang, X.-Y., Sarkar, D., Pomper, M. G., & Fisher, P. B. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.07.001 · Cited by 61
Barrera, L., Montes-Servín, E., Hernandez‐Martinez, J., Orozco‐Morales, M., Montes-Servín, E., Michel-Tello, D., Morales-Flores, R. A., Flores‐Estrada, D., & Arrieta, O. G. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2196-y · Cited by 55
Cancer-Cell-Derived IgG and Its Potential Role in Tumor Development
Kdimati, S., Mullins, C. S., & Linnebacher, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111597 · Cited by 57
Isolation and Characterization of Neutrophils with Anti-Tumor Properties
Sionov, R. V., Assi, S., Gershkovitz, M., Sagiv, J. Y., Polyansky, L., Mishalian, I., Fridlender, Z. G., & Granot, Z. (2015) · Journal of Visualized Experiments · doi:10.3791/52933 · Cited by 60
Chadda, K. R., Blakey, E. E., Davies, T., & Puthucheary, Z. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.03.038 · Cited by 54
Taleb, K., Auffray, C., Villefroy, P., Pereira, A. L., Hosmalin, A., Gaudry, M., & Bon, A. L. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502638 · Cited by 53
Wang, K., Lv, M., Chang, Y., Zhao, X., Zhao, X., Zhang, Y., Sun, Y., Wang, Z., Suo, P., Zhou, Y., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0710-0 · Cited by 55
Joseph, E. L. M., Laheurte, C., Jary, M., Boullerot, L., Asgarov, K., Gravelin, E., Bouard, A., Rangan, L., Dosset, M., Borg, C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0326 · Cited by 55
Regulatory Role of Quiescence in the Biological Function of Cancer Stem Cells
Lee, S. H., Reed-Newman, T. C., Anant, S., & Ramasamy, T. S. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10031-8 · Cited by 56
Zheng, W., Qian, C., Tang, Y., Yang, C., Zhou, Y., Shen, P., Chen, W., Yu, S., Wei, Z., Wang, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1035323 · Cited by 53
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities
Shay, G., Hazlehurst, L., & Lynch, C. C. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1345-4 · Cited by 56
New insights into metronomic chemotherapy-induced immunoregulation
Hao, Y., Yi, S., Ruan, J., Zhao, L., & Nan, K. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.028 · Cited by 57
MDSCs, ageing and inflammageing
Pawelec, G., Picard, E., Bueno, V., Verschoor, C. P., & Ostrand‐Rosenberg, S. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104297 · Cited by 54
The tumor microenvironment: a key player in multidrug resistance in cancer
Meng, L., Zheng, Y., Liu, H., & Fan, D. (2024) · ONCOLOGIE · doi:10.1515/oncologie-2023-0459 · Cited by 56
Xu, J., Song, Z., Guo, Q., & Li, J. (2016) · BioMed Research International · doi:10.1155/2016/1490738 · Cited by 53
The Role of Myeloid-Derived Suppressor Cells in Viral Infection
O’Connor, M. A., Rastad, J. L., & Green, W. R. (2017) · Viral Immunology · doi:10.1089/vim.2016.0125 · Cited by 55
Iacobaeus, E., Douagi, I., Jitschin, R., Marcusson‐Ståhl, M., Andrén, A. T., Gavin, C., Lefsihane, K., Davies, L. C., Mougiakakos, D., Kadri, N., et al. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12042 · Cited by 54
Khadge, S., Thiele, G. M., Sharp, J. G., McGuire, T. R., Klassen, L. W., Black, P. N., Dirusso, C., Cook, L. M., & Talmadge, J. E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9941-7 · Cited by 53
Self-citationThe Janus Face of Tumor Microenvironment Targeted by Immunotherapy
Buoncervello, M., Gabriele, L., & Toschi, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174320 · Cited by 53
Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications
Liu, R., Peng, L., Zhou, L., Huang, Z., Zhou, C., & Huang, C. (2022) · Antioxidants · doi:10.3390/antiox11050853 · Cited by 52
CXCL10 conditions alveolar macrophages within the premetastatic niche to promote metastasis
Shang, C., Sun, Y., Wang, Y., Shi, H., Han, X., Mo, Y., Wang, D., Ke, Y., & Zeng, X. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215667 · Cited by 51
Zheng, J., & Hao, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1333839 · Cited by 54
Emerging roles of myeloid derived suppressor cells in hepatic inflammation and fibrosis
Hammerich, L., & Tacke, F. (2015) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v6.i3.43 · Cited by 50
Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy
Mitri, D. D., Toso, A., & Alimonti, A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2261 · Cited by 50
Neutrophils at the Biological–Material Interface
Jhunjhunwala, S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6b00743 · Cited by 48
Shariatpanahi, S. P., Shariatpanahi, S. P., Madjidzadeh, K., Hassan, M., & Abedi‐Valugerdi, M. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.01.006 · Cited by 54
Katayama, Y., Tachibana, M., Kurisu, N., Oya, Y., Terasawa, Y., Goda, H., Kobiyama, K., Ishii, K. J., Akira, S., Mizuguchi, H., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700435 · Cited by 52
Xue, G., Wang, Z., Zheng, N., Fang, J., Mao, C., Li, X., Jin, G., Ming, X., & Lu, Y. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00799-6 · Cited by 51
Market, M., Tennakoon, G., & Auer, R. C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111378 · Cited by 51
Immunosuppression in Sepsis: Biomarkers and Specialized Pro-Resolving Mediators
Padovani, C. M., & Yin, K. (2024) · Biomedicines · doi:10.3390/biomedicines12010175 · Cited by 51
Sato, Y., Shimizu, K., Shinga, J., Hidaka, M., Kawano, F., Kakimi, K., Yamasaki, S., Asakura, M., & Fujii, S. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.995541 · Cited by 51
Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer
Wang, J., Liu, Y., Yu, L., Wang, Y.-Y., Chen, R., Qian, J., Hong, Z., & Su, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14991 · Cited by 49
Zhao, A., Xu, H., Kang, X., Zhao, A., & Lu, L. (2015) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2015.11.001 · Cited by 53
Li, H., Zhou, S., Wu, M., Qu, R., Wang, X., Chen, W., Jiang, Y., Jiang, X., & Xu, Z. C. (2023) · Advanced Materials · doi:10.1002/adma.202210920 · Cited by 48
Rationale for Combining Immunotherapy with Chemotherapy
Dalgleish, A. G. (2015) · Immunotherapy · doi:10.2217/imt.14.111 · Cited by 50
Loss of gastrokine-2 drives premalignant gastric inflammation and tumor progression
Menheniott, T. R., O’Connor, L., Chionh, Y. T., Däbritz, J., Scurr, M., Rollo, B., Ng, G. Z., Jacobs, S. A., Catubig, A., Kurklu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82655 · Cited by 51
Zhang, W., He, W., Shi, X., Li, X., Wang, Y., Hu, M., Ma, F., Tao, N., Wang, G., & Qin, Z. (2018) · Phytotherapy Research · doi:10.1002/ptr.6058 · Cited by 49
Zöller, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00137 · Cited by 47
Namkoong, H., Ishii, M., Fujii, H., Yagi, K., Asami, T., Asakura, T., Suzuki, S., Hegab, A. E., Kamata, H., Tasaka, S., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006955 · Cited by 48
Driving Immune Responses in the Ovarian Tumor Microenvironment
Ning, F., Cole, C. B., & Annunziata, C. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.604084 · Cited by 50
Wu, Q., Zhang, W., Lu, Y., Li, H., Yang, Y., Geng, F., Liu, J., Li, L., Pan, Y., & Li, C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111558 · Cited by 47
The immunosuppressive landscape in tumor microenvironment
Liu, W., Zhou, H., Lai, W., Hu, C., Xu, R., Gu, P., Luo, M., Zhang, R., & Li, G. (2024) · Immunologic Research · doi:10.1007/s12026-024-09483-8 · Cited by 48
Zhang, M., Yan, L., & Kim, J. A. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.42 · Cited by 50
Determinants of Organotropic Metastasis
Smith, H. A., & Kang, Y. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-041916-064715 · Cited by 48
Metadata
- Authors
- Talmadge, J. E., & Gabrilovich, D. I.
- Affiliations
- University of Nebraska Medical Center (US)
- The Wistar Institute (US)
- Corresponding author
- Talmadge, James E.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 739-752
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4358792
- OpenAlex
- W2122403898
- Cited by
- 1,148
- References
- 197
- Citations by year
- 2026: 29 · 2025: 57 · 2024: 80 · 2023: 74 · 2022: 105 · 2021: 132 · 2020: 110 · 2019: 95 · 2018: 101 · 2017: 90 · 2016: 129 · 2015: 93 · 2014: 43 · 2013: 7
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA084488, R01CA100062)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor microenvironment, T cell suppression, immune evasion, tumor progression, metastasis, multipotent progenitors
- MeSH terms
- Animals, Antigens, Differentiation, Antigens, Neoplasm, Cell Differentiation, Cell Biology, Hematopoiesis, Extramedullary, Humans, Leukemoid Reaction, Medical Oncology, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Chemokines, Cell Lineage, Tumor Escape, Hematopoietic Stem Cell Mobilization, Myeloid Cells, Myeloid Progenitor Cells, Multipotent Stem Cells, Tumor Burden, History, 20th Century, History, 21st Century, Mice, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.